Your browser doesn't support javascript.
Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
Qiang, Min; Ma, Peixiang; Li, Yu; Liu, Hejun; Harding, Adam; Min, Chenyu; Wang, Fulian; Liu, Lili; Yuan, Meng; Ji, Qun; Tao, Pingdong; Shi, Xiaojie; Li, Zhean; Li, Teng; Wang, Xian; Zhang, Yu; Wu, Nicholas C; Lee, Chang-Chun D; Zhu, Xueyong; Gilbert-Jaramillo, Javier; Zhang, Chuyue; Saxena, Abhishek; Huang, Xingxu; Wang, Hou; James, William; Dwek, Raymond A; Wilson, Ian A; Yang, Guang; Lerner, Richard A.
  • Qiang M; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Ma P; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Li Y; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Liu H; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Harding A; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
  • Min C; University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
  • Wang F; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Liu L; Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
  • Yuan M; Velox Pharmaceuticals, Changzhou, 213000, P. R. China.
  • Ji Q; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Tao P; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Shi X; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
  • Li Z; University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
  • Li T; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Wang X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Zhang Y; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Wu NC; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Lee CD; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Zhu X; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
  • Gilbert-Jaramillo J; University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
  • Zhang C; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Saxena A; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Huang X; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Wang H; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • James W; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
  • Dwek RA; University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
  • Wilson IA; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Yang G; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
  • Lerner RA; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
Adv Sci (Weinh) ; 9(1): e2102181, 2022 01.
Article in English | MEDLINE | ID: covidwho-1487434
ABSTRACT
Combinatorial antibody libraries not only effectively reduce antibody discovery to a numbers game, but enable documentation of the history of antibody responses in an individual. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has prompted a wider application of this technology to meet the public health challenge of pandemic threats in the modern era. Herein, a combinatorial human antibody library constructed 20 years before the coronavirus disease 2019 (COVID-19) pandemic is used to discover three highly potent antibodies that selectively bind SARS-CoV-2 spike protein and neutralize authentic SARS-CoV-2 virus. Compared to neutralizing antibodies from COVID-19 patients with generally low somatic hypermutation (SHM), these three antibodies contain over 13-22 SHMs, many of which are involved in specific interactions in their crystal structures with SARS-CoV-2 spike receptor binding domain. The identification of these somatically mutated antibodies in a pre-pandemic library raises intriguing questions about the origin and evolution of these antibodies with respect to their reactivity with SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Adv Sci (Weinh) Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Adv Sci (Weinh) Year: 2022 Document Type: Article